wedge
Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services
Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services BIOTROFIX - Premier Preclinical CRO - Stroke, Alzheimer's, ALS, TBI Research - Seth P. Finklestein, M.D., CEO Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services Amyotrophic Lateral Sclerosis (ALS) Animal Models & CRO Services - Lou Gehrig's Disease is a progressive neurodegenerative disease.
Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services Amyotrophic Lateral Sclerosis - ALS - Animal Models & CRO Services
 
Home
greybar
The Company
greybar
Preclinical Drug Development
greybar
Preclinical Research Services
PK/PD Studies

Acute Stroke

Stroke Recovery

Intracerebral Hemorrhage

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

Traumatic Brain Injury

Spinal Cord Injury

Muscular Dystrophy

Myocardial Infarction

Peripheral Vascular Disease

Others

Will Travel Services
greybar
The Team
greybar
News from Biotrofix
greybar
Publications
greybar
Contact Us


Well-equipped CRO laboratory
 

Amyotrophic Lateral Sclerosis (ALS) Animal Models & CRO Services

Amyotrophic Lateral Sclerosis (ALS) Animal Models & CRO Services - Lou Gehrig's Disease Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease) is a progressive neurodegenerative disease resulting in generalized muscle weakness and atrophy, and, usually, death within a few years. In the U.S., approximately 10,000 patients are newly diagnosed with ALS each year. The disease strikes men and women of all ages.

Although in most cases, the cause of ALS is unclear (sporadic), about 10% of cases cluster within families (familial ALS, fALS). The causative mutant genes in many of these families have been identified, and one of the most common is a mutation in the superoxide dismutase-1 (SOD-1) gene. When this gene is inserted into transgenic mice, the mice develop a muscle wasting disease that is very similar to human ALS.

Biotrofix has considerable experience in the use of this transgenic mouse model to test possible new treatments for both sporadic and familial ALS. This transgenic mouse strain also serves as a general model of neurodegenerative diseases and neurodegenerative treatments. Endpoints are animal survival, behavior, and histology.

Download AMYOTROPHIC LATERAL SCLEROSIS (ALS) DISEASE MODEL (.pdf)


Contact Biotrofic for Amyotrophic Lateral Sclerosis (ALS) Research

 
 
Home | The Company | Preclinical Research Services | The Team | News | Publications | Contact Us | Site Map
wedgeBiotrofix, Inc. 604 Webster Street, Needham, MA 02494 Tel: 781-786-8890 Fax: 781-465-6061


Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.